The Alzheimer’s Association International Conference (AAIC; 16–20 July 2017) was a fantastic 5-day meeting, bringing together the world’s best minds in Alzheimer’s research and care. Below we’ve collated news highlights to come out of the conference, plus you can soon expect a series of interview with speakers from the event. To kick us off, have a listen to our #NCTalks podcast with Julie Williams, Professor of Neuropsychological Genetics at Cardiff University (UK) and the Chief Scientific Advisor of the Welsh Government, to hear more about her work on susceptibility genes in Alzheimer’s disease.
AAIC 2017: One-third of dementia cases may be preventable, says new Lancet International Commission report
The Lancet International Commission on Dementia Prevention, Intervention and Care has reported that more than one-third of global dementia cases may be preventable through addressing lifestyle factors that impact an individual’s risk.
The US POINTER trial aims to examine lifestyle interventions to prevent cognitive decline and dementia in the USA.
AAIC 2017: Pipeline analysis reveals that 35 Alzheimer’s drugs are in Phase II and III clinical development
The analysis also reported an increase in Alzheimer’s drugs in development from 2016 to 2017.
Findings from four large, population-based studies have further confirmed the importance of good dietary practices in maintaining healthy brain function and reducing dementia risk.
Studies from University of Wisconsin highlight expanded risk factors for cognitive decline and Alzheimer’s disease
Non-elective hospital admissions found to result in a 60% rate of cognitive decline in data presented at AAIC 2017.
20 US states identified as ‘dementia neurology deserts’ in data presented at the 2017 Alzheimer’s Association International Conference.
A series of studies presented at AAIC have demonstrated that risk factors for dementia, such as early-life stress, may disproportionately affect African Americans, contributing to racial disparity in dementia risk.